ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
Phase 1
Terminated
- Conditions
- Carcinoma, Renal CellKidney NeoplasmsKidney Diseases
- Interventions
- Biological: AGS-16M18
- First Posted Date
- 2009-01-05
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 7
- Registration Number
- NCT00816686
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
Phase 1
Completed
- Conditions
- CarcinomaOvarian CancerOvarian DiseasesOvarian Neoplasms
- Interventions
- Biological: AGS-8M4
- First Posted Date
- 2009-01-05
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT00816764
Retrospective, Non-interventional Study of Depo-Eligard®.
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 140
- Registration Number
- NCT00811876
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: alefacept
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00808223
- Locations
- 🇱🇻
Skin and STD Clinical Centre, Riga, Latvia
🇧🇬First Municipal Hospital for Active Treatment - Sofia, Sofia, Bulgaria
🇺🇸Pediatric and Adolescent Dermatology, San Diego, California, United States
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1355
- Registration Number
- NCT00802373
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: tacrolimus ointment 0.03%Biological: MeningitecDrug: hydrocortisone acetate ointment 1%Drug: hydrocortisone butyrate ointment 0.1%Biological: AC VAX
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 260
- Registration Number
- NCT00801957
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Drug: PlaceboDrug: Solifenacin succinate
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 973
- Registration Number
- NCT00801944
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Terminated
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Drug: Amevive exposure
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT00795353
A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
Phase 3
Completed
- Conditions
- FungemiaFungal Infections
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 288
- Registration Number
- NCT00794703
ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
Phase 2
Completed
- Conditions
- Bone Loss, Age-RelatedOsteoporosis
- Interventions
- Drug: YM529 / ONO-5920
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 692
- Registration Number
- NCT00794443
© Copyright 2025. All Rights Reserved by MedPath